A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression.

"Competing interests J.H. is a full-time employee at Firestone Biotechnologies, Shanghai. The LinearDesign Algorithm was patented and owned by Baidu USA. China Pharmaceutical University and Shandong University have filed a provisional patent for the HBV mRNA vaccine listing H.Z., A.L., L.H., J.Z., Y.Y. as inventors. Other authors declare no competing interests."

"This work was supported by the Natural Science Foundation of Jiangsu Province (BK20221031 to A.L.), the National Natural Science Foundation of China (32200764, 82061138008), the National Postdoctoral Program for Innovative Talents (BX20190192, to J.H.Z.), the Fundamental Research Funds for the Central Universities (2632022YC01, 2632022ZD04), the National Key Research and Development Program (2021YFC2300603, to J.Z.), the National Science Foundation for Young Scientists of China (82001687, to J.H.Z.), the Shandong Provincial Natural Science Foundation for The Excellent Youth Scholars (ZR2023YQ066, to J.H.Z, ZR2022YQ75, to J.Q.H), and the National Natural Science Foundation of China (81972686, to J.Q.H). This study was also supported by the Projects of State Key Laboratory of Natural Medicines (SKLNMZZ2023XX) and State Key Laboratory of Microbial Technology (M2023-13). We thank the Pharmaceutical Biology Sharing Platform and the Translational Medicine Core Facility of Shandong University and China Pharmaceutical University for instrumental support. We also thank Firestone Biotechnology Co., Ltd for technical assistance with the development of ionizable lipids and thank Baidu, Inc. for authorizing Dr. Lin’s lab to use LinearDesign Algorithm freely for commercial and non-commercial purpose in this study. We thank Dr. Liang Zhang for running LinearDesign Algorithm (Baidu) to codon-optimize the mRNA sequence."